UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 2 von 38
Datensatz exportieren als...
BibTeX
Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone
The Prostate, 2014-10, Vol.74 (14), p.1462-1464
Leibowitz-Amit, Raya
Alimohamed, Nimira
Vera-Badillo, Francisco E.
Seah, Jo-An
Templeton, Arnoud J.
Knox, Jennifer J.
Tannock, Ian F.
Sridhar, Srikala S.
Joshua, Anthony M.
2014
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Leibowitz-Amit, Raya
Alimohamed, Nimira
Vera-Badillo, Francisco E.
Seah, Jo-An
Templeton, Arnoud J.
Knox, Jennifer J.
Tannock, Ian F.
Sridhar, Srikala S.
Joshua, Anthony M.
Titel
Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone
Ist Teil von
The Prostate, 2014-10, Vol.74 (14), p.1462-1464
Ort / Verlag
United States: Blackwell Publishing Ltd
Erscheinungsjahr
2014
Quelle
MEDLINE
Beschreibungen/Notizen
BACKGROUND Abiraterone acetate (AA), oral CYP17 inhibitor, is an active agent in the treatment of metastatic castrate‐resistant prostate cancer (mCRPC). METHODS We (R.L.A and N.A) retrospectively evaluated outcome in 12 men who were re‐treated with AA following prior treatment with AA at the Princess Margaret Cancer Centre. RESULTS All men were heavily pre‐treated for mCRPC with a median of four prior lines of therapy, one of which was AA (given either pre‐ or post‐chemotherapy). Eleven out of 12 (92%) men stopped their first treatment course of AA due to progression and one stopped for financial reasons. Seven men had a PSA decrease ≥50% following their first AA treatment, of which three (46%) had a PSA decrease ≥50% to AA re‐treatment. The responses to AA re‐treatment were generally short‐lived with a median biochemical progression‐free survival of 2.3 months and median treatment duration of 3.2 months. No PSA responses to AA re‐treatment were seen in five men who did not have an initial PSA response to AA. CONCLUSIONS Our data suggest that AA re‐challenge may have limited benefit in select men with mCRPC, and warrants further formal research. Prostate 74:1462–1464, 2014. © 2014 Wiley Periodicals, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0270-4137
eISSN: 1097-0045
DOI: 10.1002/pros.22861
Titel-ID: cdi_proquest_miscellaneous_1555620427
Format
–
Schlagworte
abiraterone
,
Abiraterone Acetate
,
Aged
,
Aged, 80 and over
,
Androstadienes - therapeutic use
,
Cancer therapies
,
Enzyme Inhibitors - therapeutic use
,
Humans
,
Male
,
mCRPC
,
Medical treatment
,
Men
,
Metastasis
,
Middle Aged
,
Prostate cancer
,
Prostatic Neoplasms, Castration-Resistant - drug therapy
,
Prostatic Neoplasms, Castration-Resistant - enzymology
,
re-challenge
,
Retrospective Studies
,
Steroid 17-alpha-Hydroxylase - antagonists & inhibitors
,
Steroid 17-alpha-Hydroxylase - metabolism
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX